Rosa Diabetes PhysioPD Collaboration with Pfizer to be Presented at World PK/PD Summit
Diabetes PhysioPD model used to predict long-term clinical outcomes and select doses using only summary pharmacokinetic data from a competitor's short-term Phase I clinical trial

SAN CARLOS, CA, April 20, 2011 /24-7PressRelease/ -- Rosa & Co. LLC, a drug development advisory firm with expertise in drug-disease modeling and simulation, today announced that results from its Diabetes PhysioPD collaboration with Pfizer will be presented at the Biorbis World PK/PD Summit in Cambridge, MA April 26-29, 2011. David A. Tess, Principal Scientist, of Pfizer Inc. will be presenting a 30-minutescientific presentation entitled "Creating and Using a Physiological Model to Support Development of a GPR119 Agonist Diabetes Therapy". The presentation will describe the development, testing, and use of a custom-designed Diabetes PhysioPD model, including use of the model to clarify mechanisms of action, support compound selection, select First-In-Human doses, and predict longer-term (HbA1c lowering) clinical outcomes. The model was built using literature data and only limited summary pharmacokinetic data from a competitor's short-duration phase I trial. The presentation will also highlight the extensive testing regime to which the PhysioPD model was subjected.

"We are pleased to present results from our collaboration with Pfizer. They are leaders in the adoption of systems pharmacology modeling, and this work represents some of our early successes in this process," said Dr. Ron Beaver, Rosa's Founder and CEO.

Press Release Contact Information:

Rebecca Baillie
Rosa & Co
Chief Scientist
751 Laurel St., Ste. 127
San Carlos, CA
USA 94070
Voice: 530-661-7476
Website: Visit Our Website